Saxagliptin plus metformin combination therapy

References

• De Fronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes58, 773–795 (2009).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care34(Suppl. 1), S11–S61 (2011).
   PubMed Web of Science ®Google Scholar
• Nyenwe EA, Jerkins TW, Umpierrez GE et al. Management of Type 2 diabetes: evolving strategies for the treatment of patients with Type 2 diabetes. Metabolism60, 1–23 (2011).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia52, 17–30 (2009).
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for Type 2 diabetes: an update including new drugs and 2-drug combinations. Ann. Intern. Med.154, 602–613 (2011).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of clinical endocrinologists/American college of endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract.15, 540–559 (2009).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet368, 1696–1705 (2006).
   PubMed Web of Science ®Google Scholar
• Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb. Exp. Pharmacol.203, 53–74 (2011).
   Google Scholar
• Scheen AJ. A review of gliptins in 2011. Exp. Opin. Pharmacother.13, 81–99 (2012).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of Type 2 diabetes : a critical review of head-to-head trials. Diabetes Metab. doi:10.1016/j.diabet.2011.11.001 (2011) (Epub ahead of print).
   Google Scholar
• Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad. Med.122, 71–80 (2010).
   PubMed Web of Science ®Google Scholar
• Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes. Metab.13, 193–203 (2011).
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of Type 2 diabetes. Diabetes Metab. Syndr. Obes.4, 263–271 (2011).
   PubMedGoogle Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin. Drug Metab. Toxicol.6, 1265–1276 (2010).
   PubMed Web of Science ®Google Scholar
• Halimi S, Schweizer A, Minic B et al. Combination treatment in the management of Type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc. Health Risk Manag.4, 481–492 (2008).
   PubMedGoogle Scholar
• Saxagliptin /metformin (kombiglyze XR) for Type 2 diabetes. Med. Lett. Drugs Therapeut.53, 21–22 (2011).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin + saxagliptin for Type 2 diabetes. Expert Opin. Pharmacother.13, 139–146 (2012).
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of Type 2 diabetes mellitus. Am. J. Health Syst. Pharm.67, 1515–1525 (2010).
   PubMed Web of Science ®Google Scholar
• Dhillon S, Weber J. Saxagliptin. Drugs69, 2103–2114 (2009).
   PubMed Web of Science ®Google Scholar
• Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of Type 2 diabetes mellitus. Clin. Ther.33, 1005–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med.333, 550–554 (1995).
   PubMed Web of Science ®Google Scholar
• Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs63, 1879–1894 (2003).
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J et al. Metformin hydrochloride in the treatment of Type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin. Ther.25, 2991–3026 (2003).
   PubMed Web of Science ®Google Scholar
• Consoli A, Gomis R, Halimi S et al. Initiating oral glucose-lowering therapy with metformin in Type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab.30, 509–516 (2004).
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Bonomo K et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of Type 2 diabetes mellitus. Curr. Vasc. Pharmacol.8, 327–337 (2010).
   PubMed Web of Science ®Google Scholar
• Messaoudi SE, Rongen GA, de Boer RA et al. The cardioprotective effects of metformin. Curr. Opin. Lipidol.22, 445–453 (2011).
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila.)3, 1451–1461 (2010).
   PubMed Web of Science ®Google Scholar
• Migoya EM, Bergeron R, Miller JL et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin. Pharmacol. Ther.88, 801–808 (2010).
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Patel MB, Bailey CJ. New drugs for Type 2 diabetes mellitus: what is their place in therapy? Drugs68, 2131–2162 (2008).
   PubMed Web of Science ®Google Scholar
• Henry RR, Smith SR, Schwartz SL et al. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with Type 2 diabetes. Diabetes Obes. Metab.13, 850–858 (2011).
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in Type 2 diabetes. JAMA303, 1410–1418 (2010).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet.30, 359–371 (1996).
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet.50, 81–98 (2011).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab.12, 648–658 (2010).
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin. Pharmacokinet.50, 253–265 (2011).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents – an update. Drug Safety28, 601–631 (2005).
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs71, 1441–1467 (2011).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug–drug interactions. Clin. Pharmacokinet.49, 573–588 (2010).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin. Drug Metab. Toxicol.7, 1065–1082 (2011).
   PubMed Web of Science ®Google Scholar
• Patel CG, Kornhauser D, Vachharajani N et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes. Metab.13, 604–614 (2011).
   PubMed Web of Science ®Google Scholar
• Jabbour S, Ziring B. Advantages of extended-release metformin in patients with Type 2 diabetes mellitus. Postgrad. Med.123, 15–23 (2011).
   PubMed Web of Science ®Google Scholar
• Boulton DW, Smith CH, Li L et al. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin. Drug Investig.31, 619–630 (2011).
   PubMed Web of Science ®Google Scholar
• He YL, Paladini S, Sabia H et al. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int. J. Clin. Pharmacol. Ther.46, 259–267 (2008).
   PubMed Web of Science ®Google Scholar
• Reynolds JK, Neumiller JJ, Campbell RK. Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin. Investig. Drugs17, 1559–1565 (2008).
   PubMed Web of Science ®Google Scholar
• Stenlof K, Raz I, Neutel J et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr. Med. Res. Opin.26, 2355–2363 (2010).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes with metformin alone. Diabetes Care32, 1649–1655 (2009).
   PubMed Web of Science ®Google Scholar
• DeFronzo R, Hissa M, Garber A et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Diabetes58, A147, 547-P (2009).
   Google Scholar
• Yang W, Pan CY, Tou C et al. Efficacy and safety of saxagliptin added to metformin in Asian patients with Type 2 diabetes mellitus: A randomized controlled trial. Diabetes Res. Clin. Pract.94, 217–224 (2011).
   PubMed Web of Science ®Google Scholar
• Gautier JF, Sauvanet JP. Efficacy of saxagliptin as an add-on to oral monotherapy in the Phase 3 clinical development program: Predictive factors of the treatment response in Type 2 diabetes. Ann. Endocrinol. (Paris)72, 287–295 (2011).
   PubMedGoogle Scholar
• Goke B, Gallwitz B, Eriksson J et al. Saxagliptin is non-inferior to glipizide in patients with Type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int. J. Clin. Pract.64, 1619–1631 (2010).
   PubMed Web of Science ®Google Scholar
• Göke B, Gallwitz B, Eriksson J et al. Saxagliptin vs glipizide as add-on to metformin for Type 2 diabetes mellitus (T2DM): long-term safety and efficacy. Diabetes60(Suppl. 1), Abstract 1110-P (2011).
   Google Scholar
• Allen E, Berglind N. Saxagliptin vs glipizide as add-on therapy to metformin in patients with Type 2 diabetes: a 2-year assessment of HbA1c, hypoglycaemia, and weight gain in a randomised, double-blind study. Diabetologia54(Suppl. 1), S337, 827 (2011).
   Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with Type 2 diabetes mellitus. Diabetes Metab. Res. Rev.26, 540–549 (2010).
   PubMed Web of Science ®Google Scholar
• Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes. Metab. doi:10.1111/j.1463-1326.2011.01553.x (2011) (Epub ahead of print).
   Google Scholar
• Hermans MP, Delibasi T, Farmer I et al. Effects of saxagliptin added to sub-maximal doses of metformin compared with dose escalation of metformin in Type 2 diabetes: results from the PROMPT study. Diabetologia54 (Suppl. 1), S337, 828 (2011).
   Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab.11, 611–622 (2009).
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes. Metab.13, 567–576 (2011).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Barnett AH, Donovan M et al. Saxagliptin (SAXA) add-on therapy improves glycemic control in patients (pts) with poorly controlled Type 2 diabetes (T2D) on insulin (INS) alone or INS combined with metformin (MET). Diabetes60(Suppl. 1), Abstract 1108-P (2011).
   Google Scholar
• Barnett AH, Charbonnel B, Li J et al. Saxagliptin add-on therapy to insulin with or without metformin for Type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia54(Suppl. 1), S108–S109, 243 (2011).
   Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes. Metab.11, 527–533 (2009).
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am. J. Manag. Care14, 71–75 (2008).
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in Type 2 diabetes. Curr. Med. Res. Opin.27, 1157–1168 (2011).
   PubMed Web of Science ®Google Scholar
• Yang LPH. Saxagliptin. A review of its use as combination therapy in the management of Type 2 diabetes mellitus. Drugs72(2), 229–248 (2011).
   Google Scholar
• Senior PA. Type 2 diabetes, metformin and lactic acidosis-defining the risk and promoting safe practice. Diabet Med.29(2), 161–163 (2011).
   Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care34, 1431–1437 (2011).
   PubMed Web of Science ®Google Scholar
• Roussel R, Travert F, Pasquet B et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med.170, 1892–1899 (2010).
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad. Med.122, 16–27 (2010).
   PubMed Web of Science ®Google Scholar
• Butler PC, Matveyenko AV, Dry S et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia53, 1–6 (2010).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors are favourable to GLP-1 receptor agonists: yes. Eur. J. Intern.23(2), 126–231 (2011).
   PubMedGoogle Scholar